article thumbnail

Teledyne Clears Two Antitrust Reviews For FLIR Acquisition

socalTECH

Thousand Oaks-based Teledyne Technologies Incorporated says it has cleared antitrust reviews in both Canada and Canada for its ongoing acquisition of FLIR Systems.

article thumbnail

Teledyne Completes Scientific Systems Acquisition

socalTECH

Thousand Oaks-based Teledyne Technologies said on Thursday that it has completed its acquisition of the assets of Pennsylvania-based Scientific Systems Inc. Financial details of the acquisition were not announced. READ MORE>>.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen Completes $13.4 Billion Acquisition Of Otezla

socalTECH

Thousand Oaks-based biotech giant Amgen said Thursday that it has successfully completed its acquisition of the worldwide rights to Otezla , from Celgene Corporation , in a deal that was worth $13.4 Otezla is an oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis.

article thumbnail

Teledyne Completes Bolt Technology Acquisition

socalTECH

Thousand Oaks-based Teledyne Technologies said Tuesday afternoon that it has complted its acquisition of Bolt Technology Corporation. teledyne technologies bolt technology merger acquisition marine underwater vehicle cable' The deal was worth approximately $171M, or $22.00 per share in cash. READ MORE>>.

article thumbnail

Teledyne Completes $789M e2v Acquisition

socalTECH

Thousand Oaks-based Teledyne Technologies Incorporated and UK-based e2v technologies plc said today that the two have completed the $789M acquisition of e2v by Teledyne. The deal had been announced in December. e2v develops machine vision products, including image sensors and custom cameras and applications.

article thumbnail

Amgen Completes Five Prime Therapeutics Deal

socalTECH

Thousand Oaks-based Amgen said this morning that it has successfully completed its $1.9 billion acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. Amgen paid $38.00 per share in cash for Five Prime Therapeutics.

article thumbnail

Amgen, Onyx Pharmaceuticals Get Approval On Acquisition

socalTECH

Thousand Oaks-based Amgen and Onyx Pharmaceuticals said late Wednesday that the two have received early termination of the Hart-Scott-Rodino Antitrust waiting period for Amgen''s acquisition of Onyx. cancer lifescience biotech acquisition merger amgen pharmaceuticals onyx' READ MORE>>.